8legs: Medicare

Your Followed Topics

Top 4 medicare News Today

Dr Oz says 800 hospice providers suspended in California over alleged $1B Medicare fraud scheme

#1 out of 4

crime1d ago

Dr Oz says 800 hospice providers suspended in California over alleged $1B Medicare fraud scheme

Foxnews.com

Dr. Mehmet Oz announced the suspension of 800 California hospice and home health providers amid a massive fraud crackdown.
Oz described the suspects as ‘weaponized, professional hoodlums’ exploiting weaknesses in the healthcare system.
Officials say the Los Angeles area accounted for a large share of the suspected fraud in hospice care.
The crackdown includes deferring more than a billion dollars in federal payments after audits.
The coverage notes interest from other states and support from the DeSantis administration in Florida.
Taylor Penley is cited as an associate editor with Fox News contributing to the article.
Oz holds the role of CMS Administrator under Health and Human Services leadership at the time of the report.
The piece frames the fraud crackdown as protecting patients and the Medicare Trust Fund.
The article mentions broad state and national concerns beyond California.
The report includes a visual descriptor note for a Getty image and accompanying captions.

Vote 0

Dr. Oz uses AI to perform radical surgery to remove fraud

#2 out of 4

health22h ago

Dr. Oz uses AI to perform radical surgery to remove fraud

Nypost.com

Dr. Mehmet Oz launches an AI-driven crackdown on Medicare fraud, focusing on hospice providers in California.
Investigators flagged red flags such as patients not terminally ill and billing for services never rendered.
In about 10 weeks, authorities cut off payments to hundreds of allegedly fake hospices.
Officials found 210 active agencies clustered in a single square mile.
The crackdown followed reports of dashboards and YouTube reporting on hospice clusters in LA.
Authorities cited lavish assets tied to the operation, such as a Tesla Cybertruck at one site.
The report notes public outrage and social media commentary over the fraud findings.
The piece emphasizes AI never sleeps in processing data and cross-referencing claims.
The author frames the effort as a mandate to reduce waste, fraud and abuse in federal health programs.
The story highlights California as the epicenter of healthcare fraud in the piece’s setting.

Vote 0

Blocking New Medicare Home Health And Hospice Firms Won’t Stop Fraud

#3 out of 4

health8h ago

Blocking New Medicare Home Health And Hospice Firms Won’t Stop Fraud

Forbes.com

Medicare has blocked new home health and hospice providers for at least six months, a move critics say aims to curb fraud but may restrict access.
The article argues the ban could hinder access to care in rural and underserved communities where current firms lack competition.
Critics say preventing new entrants may protect existing firms while failing to address actual fraud among current providers.
The analysis notes the Government Accountability Office estimated about $100 billion in improper payments in 2023, a fraction of nearly $1 trillion in total program spending.
The piece questions the shutdown of new entrants as a solution, suggesting stronger enforcement against existing bad actors instead.
Hospice payment mechanics are identified as a core issue, with fixed daily rates potentially misaligning incentives over time.
The author suggests boosting ownership transparency and preventing reuse of names by convicted operators as a potential fix.
Some providers exist that operate on private pay only and do not participate in government programs.
The piece notes CMS chair Mehmet Oz’s statements about blocking new entrants as a broader anti-fraud effort.
The article contrasts the ban with the need to physically limit the access to care and ensure supply in underserved areas.

Vote 0

Supreme Court rejects appeals from drug manufacturers over Medicare price negotiations

#4 out of 4

business8h ago

Supreme Court rejects appeals from drug manufacturers over Medicare price negotiations

Twincities.com and 2 more

Who/What: The Supreme Court declined to hear appeals from six pharmaceutical companies challenging Medicare drug-price negotiations, leaving the program intact.
What/When: The price-negotiation program was created in 2022 under the Inflation Reduction Act and began delivering discounts with initial deals in 2026.
Where/How: The court left in place lower-court rulings, enabling ongoing price talks and no specified end date in the statute.
Why: The administration argues the program allows Medicare to compel price talks with manufacturers, while opponents say it relies on threats rather than genuine negotiation.
What/How Much: So far, the program has negotiated lower prices for 25 Medicare-covered drugs, including Ozempic, Rybelsus, and Wegovy.
Why/Impacts: The program has become a political flashpoint, with Republicans criticizing it and Democrats defending it as cost-lowering policy.
What/Who: The case involved actions by AstraZeneca, Johnson & Johnson, Bristol Myers Squibb, Novartis, Novo Nordisk, and Boehringer Ingelheim Pharmaceuticals Inc.
What/When: The program’s discounts are projected to reach substantial figures, with Novo Nordisk’s Ozempic and Wegovy discounts anticipated to start in 2027 at 71%.
What/How: The government notes manufacturers can opt out of Medicare participation if they dislike the terms, a point argued by the Solicitor General in court.
What/Context: The program aims to lower out-of-pocket costs for seniors and disabled, with earlier years noting significant anticipated savings.

Vote 2

Explore Your Interests

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Explore Your Interests

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.